<table>
<thead>
<tr>
<th>Title</th>
<th>MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Horie, Takahiro; Nishino, Tomohiro; Baba, Osamu; Kuwabara, Yasuhide; Nakao, Tetsushi; Nishiga, Masataka; Usami, Shunsuke; Izuhara, Masayasu; Nakazeki, Fumiko; Ide, Yuya; Koyama, Satoshi; Sowa, Naoya; Yahagi, Naoya; Shimano, Hitoshi; Nakamura, Tomoyuki; Hasegawa, Koji; Kume, Noriaki; Yokode, Masayuki; Kita, Toru; Kimura, Takeshi; Ono, Koh</td>
</tr>
<tr>
<td>Citation</td>
<td>Scientific reports (2014), 4</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2014-06-16</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/188354">http://hdl.handle.net/2433/188354</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a></td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>publisher</td>
</tr>
</tbody>
</table>
MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo

Takahiro Horie1,2*, Tomohiro Nishino1*, Osamu Baba1, Yasuhide Kowabara1, Tetsushi Nakao1, Masataka Nishiga1, Shunsuke Usami1, Masayasu Izuhara1, Fumiko Nakazeki1, Yuya Ide1, Satoshi Kayama1, Naoya Sowai1, Naoya Yahagi3, Hitoshi Shimano5, Tomoyuki Nakamura4, Koji Hasegawa5, Noriaki Kume6, Masayuki Yokode2, Toru Kita7, Takeshi Kimura1 & Koh Ono1

1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan, 2Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan, 3Department of Internal Medicine (Endocrinology and Metabolism), Graduate School of Comprehensive Human Sciences, Nutrigenomics Research Group, Faculty of Medicine, and International Institute for Integrative Sleep Medicine (IIIS), World Premir International Research Center Initiative (WPI), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan, 4Department of Pharmacology, Kansai Medical University, Moriguchi, Osaka 570-8506, Japan, 5Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan, 6Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650-8586, Japan, 7Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe 650-0046, Japan.

MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation or promote mRNA degradation. Recent reports, including ours, indicated that miR-33a located within the intron of sterol regulatory element-binding protein (SREBP) 2 controls cholesterol homeostasis and can be a possible therapeutic target for treating atherosclerosis. Primates, but not rodents, express miR-33b from an intron of SREBF1. Therefore, humanized mice, in which a miR-33b transgene is inserted within a Srebf1 intron, are required to address its function in vivo. We successfully established miR-33b knock-in (KI) mice and found that protein levels of known miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced compared with those in wild-type mice. As a consequence, macrophages from the miR-33b KI mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Moreover, HDL-C levels were reduced by almost 35% even in miR-33b KI hetero mice compared with the control mice. These results indicate that miR-33b may account for lower HDL-C levels in humans than those in mice and that miR-33b is possibly utilized for a feedback mechanism to regulate its host gene SREBF1. Our mice will also aid in elucidating the roles of miR-33a/b in different genetic disease models.

SREBP proteins (SREBPs) comprise a subclass of basic helix-loop-helix leucine zipper transcription factors conserved from yeasts to humans and regulate the expression of genes required for maintaining cellular lipid homeostasis. Mammals possess two SREBP genes, SREBP-1 and SREBP-2 (known as SREBF1 and SREBF2, respectively) that express three major SREBP proteins. Two SREBP-1 isoforms, SREBP-1a and SREBP-1c, primarily regulate fatty acid metabolism, and SREBP-2 is the main regulator of cholesterol metabolism, although there is some functional overlap among the three SREBP isoforms.

MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation or promote mRNA degradation. Recent advances in the understanding of miR biology revealed that the genetic loci encoding for the transcription factors SREBP-1 and SREBP-2 also encode for the miRs miR-33a and miR-33a, respectively. Recent reports, including ours, indicated that miR-33a controls ABCA1 expression and reduces HDL-C levels and that miR-33a deficiency ameliorates atherosclerosis in mice. However, in rodents, a part of miR-33a is lacking from a Srebf1 intron (Supplementary Fig. 1a), and it is impossible to determine the precise coordinate mechanisms of miR-33a and miR-33b; the expression of these miR-33s is expected to depend on their corresponding host genes. Of note, SREBP-1 and SREBP-2 are differentially regulated by hormones, dietary...
challenges, or statin treatment, and the amounts and functions of miR-33a and miR-33b would be greatly affected under these conditions. miR-33a and miR-33b are identical in their seed sequences, and thus have been predicted to repress the same set of genes with similar specificities. Anti sense oligonucleotides against miR-33a are believed to simultaneously target miR-33a and miR-33b. However, there remains a 2-nucleotide mismatch after the seed sequence between miR-33a and miR-33b (Supplementary Fig. 1a), and whether this difference results in differential targeting remains to be established. Moreover, some of the previously established miR-33a target genes were not dysregulated in our miR-33a-deficient mice. Therefore, humanized mice, in which a miR-33b transgene is inserted within a Srebf1 intron, are required to address its function in vivo.

We successfully established miR-33b knock-in (KI) mice for the same intron as in humans. The protein levels of known miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced under basal conditions. An LXR agonist, which induces Srebf1 expression, enhanced miR-33b production. In vitro experiments indicated that macrophages from the miR-33b KI mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Moreover, HDL-C levels were reduced by almost 35% even in miR-33b KI hetero mice. Therefore, miR-33b KI strategy did not alter Srebf1 intron 16 splicing, as confirmed by PCR (Fig. 2d) and sequencing (Fig. 2e). The expression levels of miR-33b in miR-33b KI/+ mice were almost half of those in miR-33b KI/+ mice (Fig. 2f). We also measured the levels of miR-33b, miR-33a, Srebf1, and Srebf2 in WT and KI mice in both the liver and the peritoneal macrophages (Supplementary Figure S2b–d and S3a–d). Srebf1 levels were similar among these mice (Supplementary Figure S2c and S3c). Although there was no difference in miR-33a levels in macrophages (Supplementary Figure S3b), miR-33a levels were increased in proportion of the expression levels of miR-33b in the liver (Supplementary Figure S2b). The miR-33b KI/+ mice were born with the expected Mendelian ratios, were viable, fertile, and did not exhibit any obvious abnormalities in size, shape, or structure up to 8 weeks of age. Relative tissue expression pattern of miR-33b was similar to that of Srebf1 (Supplementary Fig. S2e and S2f).

miR-33b is upregulated after inducing Srebf1 expression. We next sought to confirm whether miR-33b expression was affected by endogenous changes in Srebf1 expression by the LXR agonist T0901317. When primary hepatocytes from the miR-33b KI/+ mice were stimulated with T0901317, Srebf1 and miR-33b mRNA levels were significantly increased in parallel, although this increase was faster for Srebf1 than for miR-33b (Fig. 3a and b). To check this effect in vivo, T0901317 was suspended in 0.5% carboxymethyl-cellulose and administrated to 8-week-old male miR-33b KI/+ mice at a dose of 25 mg/kg for 3 days. The average liver weight of the T0901317-treated mice was 1.5-fold greater than that of the control mice (Supplementary Fig. S4a). Srebf1 and miR-33b expression levels in the liver were also significantly increased in parallel (Fig. 3c and d). The average liver weight and Srebf1 expression level in the liver of T0901317-treated WT mice were shown in Supplementary Figure S4b and S4c. These results indicate that miR-33b was co-expressed with Srebf1 in the livers of the T0901317-treated miR-33b KI mice.

miR-33b KI results in alterations in miR-33a target proteins ABCA1 and SREBP-1. We determined ABCA1, SREBP-1, CPT1a, and AMPKα protein levels in the liver (Fig. 4a and Supplementary

---

**Figure 1** | **miR-33b is co-expressed with SREBF1 in HepG2 cells.** HepG2 cells were treated with T0901317 (10 μM) for the indicated time. The relative expressions of SREBF1 (a), miR-33b (b), SREBF2 (c), and miR-33a (d) are shown (n = 6–9). Values are mean ± s.e.m. *p < 0.05, ***p < 0.001 compared with 0 h.
Figure 2 | Generation of miR-33b knock-in (KI) mice. (a). Strategy used to generate miR-33b KI mice. (b). Southern blotting of mouse tail genomic DNA. Representative images are shown. (c). PCR analysis of mouse tail genomic DNA. Representative images are shown. (d). RT-PCR analysis of Srebf1 expression in the livers of 8-week-old mice. Sense primer was designed for exon 13, and antisense primer was designed for exon17. Note that there was no other band except for that of the correct size. Representative images are shown. (e). Sequencing alignment at the joint between exons 16 and 17 of Srebf1 in the indicated mice. (f). Relative expression of miR-33b in the livers of 8-week-old mice. Sense primer was designed for exon 13, and antisense primer was designed for exon 17. Note that there was no other band except for that of the correct size. Representative images are shown. (g). Sequencing alignment at the joint between exons 16 and 17 of Srebf1 in the indicated mice. (h). Relative expression of miR-33b in the livers of 8-week-old mice. Sense primer was designed for exon 13, and antisense primer was designed for exon 17. Note that there was no other band except for that of the correct size. Representative images are shown.

Figure S5). As shown in Fig. 4a, Supplementary Figure S5a, and S5b, ABCA1 and SREBP-1 protein levels were lower in the livers of the miR-33b KI mice. However, the protein levels of some of the previously defined miR-33a target genes, such as CPT1a and AMPKα, remained unchanged. We also analyzed protein expressions of glucose metabolic genes (Fig. 4b and Supplementary

Figure 3 | miR-33b is co-expressed with Srebf1 in miR-33b KI mice. (a). Relative Srebf1 expression levels in primary hepatocytes from miR-33b KI mice treated with T0901317 (10 μM) for the indicated time. Values are mean ± s.e.m. (n = 6). *p < 0.05 compared with the vehicle. (b). Relative miR-33b expression levels in primary hepatocytes from miR-33b KI mice treated with T0901317 (10 μM) for the indicated time. Values are mean ± s.e.m. (n = 6). **p < 0.01 compared with the vehicle. (c). Relative Srebf1 expression levels in the livers of 8-week-old male miR-33b KI mice treated with T0901317 (25 mg/kg) for 3 days. Values are mean ± s.e.m. (n = 6). ***p < 0.001 by one-way analysis of variance. (d). Relative miR-33b expression levels in the livers of 8-week-old male miR-33b KI mice treated with T0901317 (25 mg/kg) for 3 days. Values are mean ± s.e.m. (n = 6). **p < 0.01 compared with the vehicle.
Figure 4 | miR-33b regulates ABCA1 and SREBP-1. (a). Western blotting analysis for ABCA1, SREBP-1, CPT1a, and AMPKα protein levels in the livers of WT, KI+/−, and KI+/+ mice. Representative images are shown. TF2B and β-actin were used as loading controls. (b). Western blotting analysis for SRC1, PCK1, CREB and G6Pase protein levels in the livers of WT, KI+/−, and KI+/+ mice. Representative images are shown. β-actin were used as loading controls.

Figure S5c–f). However, no significant change in protein level was observed in PCK1, G6PC, and CREB in the liver of miR-33b KI mice compared with that of control mice. SRC1 was up-regulated in miR-33b KI mice and it was opposite to the results of previous report14.

miR-33b KI reduces cholesterol efflux in macrophages. To investigate a physiological role of miR-33b in mice, we first compared the functions of peritoneal macrophages from the WT and miR-33b KI+/− mice. ABCA1 and ABCG1 protein levels were lower in macrophages from the miR-33b KI+/− mice than from the WT mice (Fig. 5a and Supplementary Figure S3e and S3f), which was compatible with the findings for our miR-33a-deficient mice. We determined apoA-I- and HDL-C-mediated cholesterol efflux from peritoneal macrophages and found that macrophages from the miR-33b KI+/− mice had lower apoA-I- and HDL-C-mediated cholesterol efflux than those from the WT mice (Fig. 5b).

A single miR-33b copy reduces serum HDL levels. Hepatic ABCA1 overexpression increases HDL-C levels7, and liver-specific deletion of ABCA1 results in a substantial decrease in plasma HDL-C levels (approximately 80%) in chow-fed mice8. Moreover, we previously reported that the miR-33a−/− mice had 22%/−39% higher serum HDL-C levels than the WT mice9. Thus, we determined the serum HDL-C levels of the WT, miR-33b KI+/−, and miR-33b KI+/+ mice at the age of 8 weeks.

Serum HDL-C levels were significantly decreased in the miR-33b KI+/− and miR-33b KI+/+ mice compared with the WT mice (Table). We also classified and quantified serum lipoproteins using high-performance liquid chromatography (HPLC). Mean plots of the HPLC elution profile of serum from male mice are shown in Fig. 5c, and the lipid profiles are summarized in Supplementary Table S1. These results show that only one copy of miR-33b was sufficient to substantially reduce HDL-C and total cholesterol to the same levels as those in the miR-33b KI+/− mice. Moreover, the decreased HDL levels mainly comprised very large-, large-, and medium-sized HDLs (mature HDLs) (Fig. 5c and Supplementary Table S1).

Discussion

In the present study, we successfully established humanized mice, in which a miR-33b transgene was inserted within the same intron as that in human SREBF1. The LXR agonist T0901317, which is a well-established Srebf1 expression inducer, enhanced miR-33b production. The protein levels of known miR-33a/b target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced under basal conditions. In vitro experiments indicated that macrophages from the miR-33b KI+/− mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Finally, HDL-C levels were reduced by almost 35% even in the miR-33b KI+/− mice compared with the WT mice without any changes in triglyceride (TG) levels.

In contrast to humans and other mammals, rodents lack miR-33b and only have miR-33a in Srebf2. This needs to be kept in mind when attempting to directly translate to humans the previous results that miR-33a inhibition could prevent atherosclerosis in mouse models because of two reasons. First, SREBF1 and SREBF2 are differentially regulated by hormones, dietary challenges, and lipid-lowering agents, including statins21. This indicates that both isoforms of miR-33 participate in regulating the primary risk factors of metabolic syndrome, which accelerate atherosclerosis. Second, miR-33b differs from miR-33a by 2-nucleotides and may have a different target profile, including stronger effects on targets in the SREBP-1-dependent regulation of fatty acid/TG homeostasis and insulin signaling. We found increased miR-33b expression after treatment with LXR agonist in our mice, which indicated that miR-33b was co-expressed with its Srebf1 host gene and enabled us to study the impact of Srebf1-derived miR-33b on cholesterol/lipid homeostasis.

We have not yet succeeded in identifying miR-33b-specific target genes. Even previously reported miR-33b target genes were not reduced in the liver of miR-33b KI mice compared with that of control mice. One of the reasons of such result may be that the previous study was conducted in human cell line and potential binding sites of miR-33b are not conserved at least in PCK1 3′UTR of mice. It is also possible that some compensated mechanisms may have occurred in miR-33b KI mice. However, the protein levels of miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced20. Moreover, the protein levels of previously defined miR-33a target genes, which were not dysregulated in miR-33a KO mice, including CPT1a and AMPKα, remained unchanged28. Thus, it may be necessary to assess those conditions when Srebf1 expression is strongly affected to establish the importance of the functions of miR-33b. In any event, the numbers of miR-33b transcripts were greater than those of miR-33a transcripts, and this underscores the importance of miR-33b22. Although there were no differences in the levels of miR-33a in macrophages, it is interesting that the levels of miR-33a were increased in proportion to the expression levels of miR-33b in the liver. Because Srebf1 level is higher in the liver than that in macrophages22, it is possible that miR-33b and miR-33a compete for the same target gene binding sites in the liver, and that the degradation of miR-33a is inhibited by miR-33b expression. In addition, there may be other unknown mechanisms.
miRs are known to target long non-coding RNAs whose functions are largely unknown, and interactions between miRs are also possible\(^1\). Thus, miR-33b-specific functions should be determined in future experiments.

Rayner et al. recently showed that inhibiting miR-33a and miR-33b in healthy male non-human primates increased circulating HDL-C levels\(^2\). More recently, Rottiers et al. reported that miR-33a and miR-33b acted in a redundant manner and that inhibiting both isoforms by an 8-mer LNA-modified anti-miR enhanced HDL-C levels\(^3\). Our data demonstrated that miR-33b indeed functions to reduce HDL-C levels to the same levels as those in the miR-33b KO experiments\(^8\), we did not observe any changes in TG levels, indicating that modulation of miR-33s is unlikely to have a strong effect on TG levels, although species differences and different dietary conditions need to be considered.

In contrast, we found a significant inhibitory effect of miR-33b on SREBP-1. A feedback system of SREBP-2 by cholesterol levels is well known, which maintains appropriate levels of cellular cholesterol.

### Table | Serum profiling of WT, KI\(^{-/-}\), and KI\(^{+/+}\) mice

<table>
<thead>
<tr>
<th>Parameter</th>
<th>WT (n = 4)</th>
<th>KI(^{-/-}) (n = 4)</th>
<th>KI(^{+/+}) (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP (g/dL)</td>
<td>4.375 ± 0.1109</td>
<td>4.275 ± 0.04787</td>
<td>4.350 ± 0.05000</td>
</tr>
<tr>
<td>ALB (g/dL)</td>
<td>2.950 ± 0.1190</td>
<td>2.825 ± 0.1109</td>
<td>2.900 ± 0.04082</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>21.75 ± 0.6801</td>
<td>20.58 ± 1.248</td>
<td>21.58 ± 1.680</td>
</tr>
<tr>
<td>CRE (mg/dL)</td>
<td>0.1125 ± 0.00250</td>
<td>0.0925 ± 0.004787</td>
<td>* 0.0975 ± 0.006292</td>
</tr>
<tr>
<td>Na (mEq/l)</td>
<td>152.5 ± 0.6455</td>
<td>153.5 ± 0.2887</td>
<td>153.8 ± 0.4787</td>
</tr>
<tr>
<td>K (mEq/l)</td>
<td>3.350 ± 0.05000</td>
<td>3.325 ± 0.0750</td>
<td>3.350 ± 0.1041</td>
</tr>
<tr>
<td>Cl (mEq/l)</td>
<td>110.5 ± 0.6455</td>
<td>110.8 ± 0.2500</td>
<td>111.0 ± 0.5774</td>
</tr>
<tr>
<td>Ca (mg/dL)</td>
<td>8.500 ± 0.1871</td>
<td>8.325 ± 0.1109</td>
<td>8.350 ± 0.08660</td>
</tr>
<tr>
<td>IP (mg/dL)</td>
<td>7.775 ± 0.4589</td>
<td>7.225 ± 0.2955</td>
<td>7.400 ± 0.4637</td>
</tr>
<tr>
<td>TBIL (mg/dL)</td>
<td>0.0875 ± 0.004787</td>
<td>0.0925 ± 0.008539</td>
<td>0.0825 ± 0.01109</td>
</tr>
<tr>
<td>AST (IU/l)</td>
<td>39.25 ± 1.702</td>
<td>33.50 ± 1.658</td>
<td>39.25 ± 1.702</td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>26.50 ± 3.663</td>
<td>21.00 ± 2.415</td>
<td>22.75 ± 1.702</td>
</tr>
<tr>
<td>ALP (IU/l)</td>
<td>505.5 ± 48.55</td>
<td>398.5 ± 40.01</td>
<td>480.0 ± 29.31</td>
</tr>
<tr>
<td>LDH (IU/l)</td>
<td>278.3 ± 77.21</td>
<td>243.5 ± 55.30</td>
<td>255.0 ± 55.26</td>
</tr>
<tr>
<td>AMY (IU/l)</td>
<td>2295 ± 68.22</td>
<td>2224 ± 62.39</td>
<td>2363 ± 97.02</td>
</tr>
<tr>
<td>γ-GTP (IU/l)</td>
<td>3&gt;</td>
<td>3&gt;</td>
<td>3&gt;</td>
</tr>
<tr>
<td>T-CHO (mg/dL)</td>
<td>98.50 ± 5.694</td>
<td>66.25 ± 2.287</td>
<td>** 62.00 ± 1.225</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>34.75 ± 2.780</td>
<td>32.25 ± 3.065</td>
<td>35.25 ± 4.328</td>
</tr>
<tr>
<td>NEFA (μEq/L)</td>
<td>471.0 ± 47.36</td>
<td>474.8 ± 71.81</td>
<td>459.5 ± 55.01</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>6.750 ± 0.6292</td>
<td>6.750 ± 0.6292</td>
<td>6.000 ± 0.0</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>57.75 ± 4.171</td>
<td>39.25 ± 0.7500</td>
<td>** 37.25 ± 0.6292</td>
</tr>
<tr>
<td>GLU (mg/dL)</td>
<td>216.3 ± 22.98</td>
<td>180.5 ± 8.930</td>
<td>197.8 ± 11.92</td>
</tr>
</tbody>
</table>

Values are mean ± s.e.m. Blood was obtained from chow-fed 8-wk-old male mice after 4 h fasting.

\(p < 0.05; \quad **p < 0.01; \quad ***p < 0.001\) compared with WT mice.

Figure 5 | miR-33b reduces cellular cholesterol efflux and serum HDL-C levels. (a) Western blotting for ABCA1 and ABCG1 proteins in peritoneal macrophages from WT and KI\(^{+/+}\) mice. Representative images are shown. β-actin was used as the loading control. (b) Cholesterol efflux to apoA-I and HDL-C in peritoneal macrophages from WT and KI\(^{+/+}\) mice (n = 6 each). Values are mean ± s.e.m. ***p < 0.001 (c). Mean plots of HPLC analysis for serum cholesterol in WT and KI\(^{+/+}\) mice (n = 4 and 5, respectively).
However, a similar mechanism has not been established for SREBP-1. Chronic activation of SREBP-1c in cases of overnutrition can lead to serious obesity-related problems. miR-33b may be utilized for a feedback mechanism to regulate its host gene SREBF1 because insulin induces hepatic SREBP-1c expression and promotes lipogenesis and hepatic TG synthesis (Supplementary Fig. S6).

In the present study, we demonstrated the effect of miR-33b on HDL-C levels in vivo. We assume that inhibiting both miR-33a and miR-33b will have a significant effect on HDL-C levels in clinical settings. However, it is known that one miR can have hundreds of target genes and unexpected side effects may occur due to long-term therapeutic modulation of miR-33 to cure metabolic diseases. Careful observations of miR-33a KI and miR-33a-deficient mice and intercrossing of these mice will enable us to detect miR-33a- and miR-33b-specific target genes and to elucidate the overall functions of miR-33a and miR-33b in vivo. Moreover, our mice will aid in analyzing the roles of miR-33a/b in different genetic disease models and in screening drug candidates that can modulate miR-33a and miR-33b levels and activities.

Methods

Materials

The following antibodies were used: anti-ABCA1 (NB400-105) and anti-APOB1 (NB400-132) (Novus Biologicals, Littleton, CO, USA); anti-AMPKa(1) (ab285328) and anti-CREB (ab91979) (Cell Signaling Technology, Beverly, MA, USA); anti-CPT1a (ab128568) and anti-CPT1b (ab270358) (Abcam, Cambridge, UK); anti-β-actin (AC-15; A5451, Sigma-Aldrich, St. Louis, MO, USA); anti-SREBP-1 (sc-13551, sc-9984), anti-SREBP (sc-8995), anti-G6Pase (sc-27198), and anti-TF2β (sc-225) (Santa Cruz, Biotechnology, California, USA); anti-GAPDH, anti-β-actin and anti-goat IgG HRP-linked antibodies were purchased from GE Healthcare (Amerham, UK). Human apoA-I was purchased from Sigma-Aldrich. Human acetylated LDL (acLDL) and human LDL-C were purchased from Biomedical Technologies, Inc. (Stoughton, MA, USA). [1, 2-3H (N)]-Cholesterol was purchased from Perkin Elmer (Boston, MA, USA). | 4 : 5312 | DOI: 10.1038/srep05312

Generation of miR-33b KI mice. A targeting vector was constructed by modifying bacterial artificial chromosome RP24-310C22 (Invitrogen) using a defective anti-sense, GTAGCCAACGCTATGTCCTGATAG. 5′ probe sense, CACGGTTGTGAGAAGTCAGTATTC; 5′ probe antisense, GCTGCCACGACdC-1

RNA extraction and quantitative RT-PCR (qRT-PCR). Total RNA was isolated and purified using TriPure Isolation Reagent (Roche). cDNA was synthesized from 1 μg of total RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s instructions. For qRT-PCR, specific genes were amplified in 40 cycles using SYBR™ Green PCR Master Mix (Applied Biosystems). Expression was normalized to that of the housekeeping gene β-actin. Gene-specific primers are as follows:

- SREBF1 sense, AACAGCTCCACACTGTCTGAGAT; SREBF1 antisense, GTTGCTGAGAAAGGATGTA; SREBF2 sense, AGGAGAACATGTTGCTGA; SREBF2 antisense, TAAAAGGACAAGGACAGGAG; ACTB sense, AGAGCCA-CTTCCACACTGTCTC; ACTB antisense, GCACATTGTTGCGGATTGAG; SREBF1 sense, TAGAACATACCCCAGGAGTG; SREBF1 antisense, GTCACGGCGACC- AAGAAGTA; SREBF2 sense, GTGAGGACCTCTCAAGCTCA; SREBF2 antisense, GTTGAAGTCTTACACAGGAG; Actb sense, GATCGTGCACAACCACACTCCT; Actb antisense, GGGGTTGTGAAAGGTCTCAAA.

Quantitative PCR for miRs. Total RNA was isolated using the TriPure Isolation Reagent (Roche). miR-33a and miR-33b were measured using TaqMan MicroRNA assay protocols (Applied Biosystems). Products were analyzed using a thermal cycler (ABI Prism® 7900HT sequence detection system). miR expression levels of samples were normalized by using results of U6 snRNA as control.

Biochemical serum analysis. After mice were fasted for 4-6 h, blood was obtained from the inferior vena cava of an anesthetized mouse, and serum was separated by centrifugation at 4 °C and stored at -80 °C. Employing standard methods, biochemical measurements were made using a Hitachi 7100 Auto Analyzer (Nagahama Life Science Laboratory, Nagahama, Japan). Lipoproteins were analyzed by HPLC at Skylight Biotech (Akita, Japan), according to the procedures described previously.11

Analysis of splicing between exons 16 and 17 in Srebf1. We amplified the fragment between Srebf1 exons 13 and 17 using cDNA from the livers of the indicated mice by PCR, and these products were then electrophoresed. Extension time was sufficient to expand the fragment when the correct splicing did not occur. There was no other band except for that of the correct size. Sequencing was performed using a primer for exon 16 and an ABI 3130 genetic analyzer. Primer sequences used were as follows:

- Exon 13 sense, CCTAGAGGAGGGTTGAACT; Exon 17 antisense, CTACCT- GAGCTAACTGTTGGTGTT; and Exon 16 sequence primer, ACGGGACACTGTTGAC- TCTTC.

Cell culture. HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Nacalai Tesque, Japan) supplemented with 10% fetal bovine serum (FBS). Mouse primary hepatocytes were obtained from miR-33b KI mice using a two-step collagenase perfusion method. In brief, hepatocyte suspensions were obtained by passing a collagenase type II (Gibco BRL, Life Technologies Inc., Rockville, MD, USA)-digested liver sample through a 70-μm cell strainer, followed by centrifugation to isolate mature hepatocytes. Hepatocytes were then resuspended in DMEM supplemented with 10% FBS and seeded on collagen type I-coated dishes (Iwaki Asahi Glass Co., Ltd.) at a density of 7 × 10⁶ cells/ml. After incubation for 24 h, the cells were used for experiments.

Cholesterol efflux from macrophages. Cellular cholesterol efflux via apoA-1 was determined as described previously.24 In brief, thioglycollate-elicited mouse peritoneal macrophages were plated in 24-well microplates at a density of 5 × 10⁶ cells/ml. Cells were cultured for 24 h in RPMI 1640 containing 0.1 μCi/ml of [3H]-cholesterol and 25 μg/ml acLDL. On the next day, the cells were washed 3 times with RPMI 1640 and incubated for 6 h in RPMI 1640 with or without apoA-1 (10 μg/ml) or HDL (100 μg/ml). Cholesterol efflux was expressed as the percentage of radioactivity released from cells in medium relative to the total radioactivity in cells plus medium.

Western blotting. Western blotting was performed using standard procedures as described previously. A lysis buffer was supplemented with a complete mini protease inhibitor (Roche), ALLN (25 μg/ml), 0.5 mM NaF, and 10 μM Na3VO4 just prior to use. Protein concentrations were determined using a bicinchoninic acid protein assay kit (Bio-Rad). All samples (20 μg of protein) were suspended in lysis buffer, fractionated using NuPAGE 4%–12% Bis-Tris (Invitrogen) gels, and transferred to a Protran nitrocellulose transfer membrane (Whatman). The membrane was blocked using 1× phosphate-buffered saline (PBS) containing 5% non-fat milk for 1 h and incubated with a primary antibody (anti-ABCA1 (1:1000), anti-APOB1 (1:1000), anti-AMPK (1:1000), anti-SREBF1 (1:250), anti-TF2B (1:1000), anti-β-actin (1:3000), anti-CREB (1:1000), anti-PCK1 (1:1000), anti-SRC1 (1:200), anti-G6Pase (1:200) or anti-CPT1a (1:1000) overnight at 4 °C. After washing with PBS–0.05% Tween 20 (0.05% T-PBS), the membrane was incubated with a secondary antibody (anti-rabbit, anti-mouse and anti-goat IgG HRP-linked; 1: 2000) for 1 h at 4 °C. The membrane was then washed with 0.05% T-PBS and detected with an ECL Western Blotting Detection Reagent (GE Healthcare) using an LAS-1000 system (Fuji Film).


**Acknowledgments**

We thank Neal G. Copeland (Institute of Molecular and Cell Biology, Singapore) for the defective prophage λ. Red recombination system; Junji Takeda (Osaka University, Osaka, Japan) and Kosuke Yusa (Osaka University, Osaka, Japan) for the plasmid used for the construction of the targetting vector; Ken-ichi Yamamura (Kumamoto University, Kumamoto, Japan) and Kimi Araki (Kumamoto University) for Ayu-J Cell expressing mice. This work was supported in part by grants from the Japan Society for the Promotion of Science, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T. Kimura, T. Kita, K.H., T.H., and K.O.), by a Grant-in-Aid for Scientific Research on Innovative Areas “Crosstalk between transcriptional control and energy pathways, mediated by hub metabolites” (3307) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to K.O.), by grants from ONO Medical Research Foundation, the Cell Science Research Foundation, Suzuken Memorial Foundation, Sakakibara Memorial Foundation, Japan Foundation of Applied Enzymology, SENSMIN Medical Research Foundation, Kowa Life Science Foundation, and ONO Medical Research Foundation (to T.H.), and by grants from ONO Medical Research Foundation, the Cell Science Research Foundation, Daichi-Sankyo Foundation of Life Science, and Takeda Memorial Foundation (to K.O.).

**Author contributions**


**Additional information**

Supplementary information accompanies this paper at http://www.nature.com/scientificreports

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Horie, T. et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. *Sci. Rep.* **4**, 5312; DOI:10.1038/srep05312 (2014).